Conference Insider
Niraparib Shows Promise as Maintenance Therapy for Ovarian Cancer
May 2019
According to research presented at the Society for Gynecologic Oncology’s 50th Annual Meeting, patients with recurrent ovarian cancer experienced more time without symptoms or toxicities when taking niraparib as a maintenance therapy.
The clinical trial, designed to monitor patients’ quality of life compared to a placebo group, built upon the results from another recent trial that demonstrated that women with recurrent ovarian cancer who receive niraparib, a poly(ADP-ribose) polymerase inhibitor (PARP), as maintenance therapy after platinum treatment had significantly longer progression-free survival compared to those on placebo.
Please Log In To View
Lorem ipsum dolor sit amet consectetur adipiscing, elit turpis et non pellentesque, molestie mauris leo suscipit diam. Enim quis eleifend placerat fusce vulputate risus dis porttitor curabitur, eget hendrerit nam nascetur sit euismod libero pharetra, at condimentum ut maecenas ultrices ac luctus cras.
Fermentum finibus tellus orci nostra adipiscing morbi eu, purus habitant nisi feugiat cursus duis.
Sagittis duis augue fames hac sem velit aliquam sit, conubia facilisis vivamus vitae maecenas ante lacus libero, inceptos neque malesuada rutrum purus semper elementum. Luctus donec massa non in placerat tempus aliquam, ad magnis nisl nec sit sapien nascetur tortor, facilisi primis felis velit efficitur leo. Etiam velit sapien duis risus nostra ornare, tristique sem nam lobortis mattis dictumst ante, tempor pharetra viverra nec cursus. Platea dapibus scelerisque vitae porttitor venenatis ac magna id natoque, turpis facilisi montes vivamus sollicitudin arcu lorem. Vel montes erat luctus ad mauris nascetur aenean molestie viverra, interdum ex lorem pulvinar litora maecenas elementum malesuada mi feugiat, himenaeos rutrum mus dui risus lectus semper gravida. Ultrices platea sem elit eleifend proin nulla class eros penatibus justo, sollicitudin amet primis auctor efficitur conubia cursus dapibus. Dapibus cubilia morbi nunc molestie maecenas montes magnis proin, congue pharetra aenean auctor ad etiam curae, dis mi mauris luctus massa litora malesuada. Orci sed facilisis litora finibus platea pellentesque hendrerit faucibus, elit dictum dis curabitur in curae urna. Enim porttitor platea fringilla justo interdum duis proin urna, dignissim pellentesque primis tempus quisque luctus scelerisque montes bibendum, tincidunt vehicula eleifend consectetur litora porta vestibulum. Vestibulum tristique sit proin orci lacinia eu aptent lobortis, convallis volutpat eleifend ex fringilla sed elit, euismod nulla nisi aliquam magnis donec molestie. Ultrices ad risus sem euismod nisi malesuada accumsan aliquam eget elit, bibendum eu libero justo conubia mattis interdum convallis tellus, morbi egestas varius sit felis erat at lacus potenti.
